Sat, Dec 27, 2014, 9:39 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Protalix BioTherapeutics, Inc. (PLX) Message Board

  • woodbarn woodbarn Jun 25, 2013 3:30 PM Flag

    Pfizer would have gotten around $12 million anyway that is assuming 60/40 profits split and 50% profit margin.

    Pfizer would have gotten around $12 million anyway that is assuming 60/40 profits split and 50% profit margin. $40 million in revenue would generate about $20 million in profits, assuming 50% profit margin. Under 60/40 profit split Pfizer would get $12 million and Protalix would get $8.

    So if Protalix can manage to get more market share, total is around $70-$80 million, Protalix has a chance to make more profits since Pfizer's profits are capped at $12.5 million a year. If Protalix can generate $70 million revenue, profit would be around $35 million, and Protalix would keep $22.5 million and Pfizer would get $12.5 million.

    50% profit margin was about the margin from previous short-term supply agreement with Brazil in 2010, figures are in Protalix's Feb 2011 10-K. In one quarter, Pfizer reported $21 million Uplyso revenue, and Protalix got 40% or $4.6 million profit. Total profit comes out to around $11 million. Product is relatively cheap, cost of product was around $800,000 and sold to Pfizer for around $2 million.

 
PLX
1.83-0.02(-1.08%)Dec 26 4:02 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Prothena Corporation plc
NASDAQFri, Dec 26, 2014 4:00 PM EST
TherapeuticsMD, Inc.
AMEXFri, Dec 26, 2014 4:01 PM EST